The customer observed (b)(6) results while using the (b)(6) on the prism 6 channel analyzer.The customer indicated that 24 specimens, which had been initial and (b)(6), were (b)(6) when tested using the western blot method.There was no adverse impact to patient management reported.No additional patient information has been provided.
|
Further evaluation of the customer issue included a review of the complaint text, review of data provided by the customer, in-house testing, batch record review, a search for similar complaints, and a review of product labeling.Return material was not available.The review of the customer data indicated that the initial and repeat reactive rates are within ranges of the specificity performance listed in the prism hcv package insert.The concomitant assay was also evaluated; a specificity testing protocol was executed in-house using lot 45613li00; testing met the acceptance criteria and determined the reagent is performing acceptably.No issues were identified, that related to the complaint under investigation, from the batch record review.Tracking and trending did not identify an adverse trend.Labeling was reviewed and found to be adequate.Based on the available information no product deficiency of the prism 6 channel-ce analyzer, list number 6a36, was identified.
|